Premium
Treatments used for obsessive–compulsive disorder—An international perspective
Author(s) -
Brakoulias Vlasios,
Starcevic Vladan,
Albert Umberto,
Arumugham Shyam Sundar,
Bailey Brenda E.,
Belloch Amparo,
Borda Tania,
Dell'Osso Liliana,
Elias Jason A.,
Falkenstein Martha J.,
Ferrao Ygor A.,
Fontenelle Leonardo F.,
Jelinek Lena,
Kalogeraki Leto,
Kay Brian,
Laurito Luana D.,
Lochner Christine,
Maina Giuseppe,
Marazziti Donatella,
Martin Andrew,
Matsunaga Hisato,
Miguel Euripedes C.,
Morgado Pedro,
Mourikis Irakis,
Pasquini Massimo,
Perez Rivera Rodrigo,
Potluri Sriramya,
Reddy Janardhan Y.C.,
Riemann Brian C.,
Rosario Maria Conceição,
Shavitt Roseli G.,
Stein Dan J.,
Viswasam Kirupumani,
Wang Zhen,
Fineberg Naomi A.
Publication year - 2019
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/hup.2686
Subject(s) - fluvoxamine , aripiprazole , exposure and response prevention , risperidone , psychiatry , medicine , deep brain stimulation , obsessive compulsive , psychosurgery , fluoxetine , psychology , clinical psychology , schizophrenia (object oriented programming) , receptor , disease , parkinson's disease , serotonin
Objective The objective of this study was to characterise international trends in the use of psychotropic medication, psychological therapies, and novel therapies used to treat obsessive–compulsive disorder (OCD). Methods Researchers in the field of OCD were invited to contribute summary statistics on the characteristics of their samples. Consistency of summary statistics across countries was evaluated. Results The study surveyed 19 expert centres from 15 countries (Argentina, Australia, Brazil, China, Germany, Greece, India, Italy, Japan, Mexico, Portugal, South Africa, Spain, the United Kingdom, and the United States) providing a total sample of 7,340 participants. Fluoxetine ( n = 972; 13.2%) and fluvoxamine ( n = 913; 12.4%) were the most commonly used selective serotonin reuptake inhibitor medications. Risperidone ( n = 428; 7.3%) and aripiprazole ( n = 415; 7.1%) were the most commonly used antipsychotic agents. Neurostimulation techniques such as transcranial magnetic stimulation, deep brain stimulation, gamma knife surgery, and psychosurgery were used in less than 1% of the sample. There was significant variation in the use and accessibility of exposure and response prevention for OCD. Conclusions The variation between countries in treatments used for OCD needs further evaluation. Exposure and response prevention is not used as frequently as guidelines suggest and appears difficult to access in most countries. Updated treatment guidelines are recommended.